BioHarvest Sciences Inc.

Good morning, and welcome to the BioHarvest Sciences First Quarter 2026 Financial Results Conference Call. As a reminder, all participants are in listen-only mode. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. As a reminder, this conference is being recorded. I will now hand the call over to Dori Kurowski of LifeSci Advisors. Please go ahead.

Greetings and welcome to the BioHarvest Sciences First Quarter 2026 Financial Results Conference Call. With us on the call this morning are Dr. Zaki Rakib, Chief Executive Officer, Bart Dichter, Chief Financial Officer, and Nilan Sobel, Director of the Board and Co-Founder. Before we begin, I'd like to remind you that management will be making projections and forward-looking statements on the call today regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review BioHarvest Sciences SEC filings, including the company's most recent Form 6K, which identify risks and uncertainties that may cause future actual results or events to differ materially. These filings can be found on the company website, as well as the SEC's website at www.sec.gov. Please note that the forward-looking statements made during today's call speak only to the date they are made, and BioHarvest Sciences undertakes no obligation to update them. And with that, I would like to turn the call over to Dr. Zakir Raqib, Chief Executive Officer of BioHarvest Sciences.

Thank you, Dori, and thank you all for joining us this morning. BioHarvest Sciences is an industrial plant cell culture biotech company and a leader in botanical synthesis, which is a patented non-GMO platform technology that industrializes what nature otherwise does slowly and produces high-value plant-derived compounds and botanical compositions without growing the plant itself. Using proprietary plant cell biology, elicitation technologies, AI-driven development and industrial-scale bioreactors, BioHarvest creates highly consistent, bioavailable, and patent-protected precision botanics, or compounds possessing enhanced potency and purity compared to the original plant, along with the characteristics for commercial scalability. The platform has already demonstrated significant commercial validation through Vinia, BioHarvest's flagship blood flow health product, while also serving as the foundation of the company's rapidly expanding CDMO business across pharmaceutical, nutraceutical, nutrition, cosmetic, and fragrance markets. With more than $100 million invested in its platform technology, 15 patents, multidisciplinary scientific capabilities, as demonstrated in various clinical publications and proven industrial-scale manufacturing, BioHarvest has two businesses representing its dual growth engines. The D2C business that has already generated cumulative vineyard-based sales of close to $100 million, and the CDMO business that is well positioned as a strategic partner for next-generation plant-based innovation across the nutraceutical, pharmaceutical, cosmeceutical, and nutrition industries. These two businesses have different operating models that have compelled the operating changes we have recently communicated. The Two Lens framework for managing the company is designed to optimize performance, capital allocation and growth execution. As such, and as announced last quarter, we will be reporting revenues and operations with this Two Lens approach. With this, Bar will provide a more detailed summary of our numbers for this quarter. Bar?